Vanguard Group Inc Alnylam Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,565,452 shares of ALNY stock, worth $6.09 Billion. This represents 0.1% of its overall portfolio holdings.

Number of Shares

13,565,452

Previous 13,297,139 2.02%

Holding current value

$6.09 Billion

Previous $4.34 Billion 42.66%

% of portfolio

0.1%

Previous 0.07%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	BUY	$311.12 - $482.13 $83.5 Million - $129 Million	268,313 Added 2.02%	13,565,452 $6.19 Billion
Q2 2025 Aug 11, 2025	BUY	$224.32 - $326.09 $54 Million - $78.4 Million	240,534 Added 1.84%	13,297,139 $4.34 Billion
Q1 2025 May 09, 2025	BUY	$233.07 - $290.7 $75.3 Million - $94 Million	323,206 Added 2.54%	13,056,605 $3.53 Billion
Q4 2024 Feb 11, 2025	BUY	$232.27 - $300.43 $22.8 Million - $29.5 Million	98,303 Added 0.78%	12,733,399 $3 Billion
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $29.8 Million - $36.5 Million	127,318 Added 1.02%	12,635,096 $3.48 Billion

Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $73.6 Million - $127 Million	513,517 Added 4.28%	12,507,778 $3.04 Billion
Q1 2024 May 10, 2024	BUY	$146.51 - $198.2 $7.38 Million - $9.98 Million	50,366 Added 0.42%	11,994,261 $1.79 Billion
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $43.5 Million - $56.4 Million	287,064 Added 2.46%	11,943,895 $2.29 Billion
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $5.23 Million - $6.48 Million	30,608 Added 0.26%	11,656,831 $2.06 Billion
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $3.34 Million - $3.83 Million	18,056 Added 0.16%	11,626,223 $2.21 Billion
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $18.5 Million - $23.8 Million	101,051 Added 0.88%	11,608,167 $2.33 Billion
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $84.2 Million - $110 Million	453,808 Added 4.11%	11,507,116 $2.73 Billion
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $1.51 Million - $2.52 Million	10,870 Added 0.1%	11,053,308 $2.21 Billion
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $25.7 Million - $36.1 Million	213,294 Added 1.97%	11,042,438 $1.61 Billion
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $16.1 Million - $22 Million	126,373 Added 1.18%	10,829,144 $1.77 Billion
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $14.1 Million - $18.5 Million	88,189 Added 0.83%	10,702,771 $1.81 Billion
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $19.8 Million - $24.3 Million	116,888 Added 1.11%	10,614,582 $2 Billion
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $1.35 Billion - $1.86 Billion	10,497,694 New	10,497,694 $1.78 Billion

Others Institutions Holding ALNY

# of Institutions

915

Shares Held

115M

Call Options Held

1.26M

Put Options Held

1.49M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Alnylam Pharmaceuticals, Inc. Transaction History